Monday, December 20, 2021 2:50:52 PM
But a Covid EUA is coming. Virtually all currently authorized mAbs are useless against Omicron. Lenz has 154% efficacy for patients with CRP<150mg/l. Lenz is variant agnostic so it will have the same efficacy against Omicron as previous variants. Lenz is the most obvious way to treat newly hospitalized Omicron patients. While there is no guarantee that lenzilumab will get the EUA this winter, I think the chances are better that it will than won't.
So HGEN is a safe long term investment because of the the growing potential for GM-CSF inhibition but has a high chance of going 5x-20x in the next few months if lenz gets the Covid EUA. It is an easy choice to stay invested. I just went back to 100% invested in HGEN.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM